Emergent BioSolutions (EBS) Depreciation and Depletion (2021 - 2026)

Emergent BioSolutions' Depreciation and Depletion history runs 6 years deep, the most recent figure standing at $7.0 million for Q1 2026.

• On a quarterly basis, Depreciation and Depletion fell 23.08% year-over-year to $7.0 million in Q1 2026; TTM through Mar 2026 was $28.6 million, a 30.41% decrease from a year earlier, with the FY2025 full-year figure at $30.7 million, down 29.75% from the prior year.
• Depreciation and Depletion slipped to $7.0 million in Q1 2026 per EBS's latest filing, from $7.2 million in the prior quarter.
• Across five years, Depreciation and Depletion topped out at $28.5 million in Q2 2022 and bottomed at $7.0 million in Q1 2026.
• The 5-year median for Depreciation and Depletion is $11.7 million (2023), against an average of $13.2 million.
• Across the five-year window, Depreciation and Depletion surged 54.05% in 2022 and sank 42.36% in 2023, its largest moves.
• Year by year, Depreciation and Depletion stood at $18.0 million in 2022, then fell by 25.56% to $13.4 million in 2023, then fell by 27.61% to $9.7 million in 2024, then fell by 25.77% to $7.2 million in 2025, then declined by 2.78% to $7.0 million in 2026.
• Per Business Quant, the three latest EBS Depreciation and Depletion figures stand at $7.0 million (Q1 2026), $7.2 million (Q4 2025), and $7.1 million (Q3 2025).